Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Ash Stevens, Inc.
RIVERVIEW, Mich., May 1, 2014 /PRNewswire/ -- Ash Stevens, Inc., a leading provider of global contract pharmaceutical drug substance development and active pharmaceutical ingredient (API) manufacturing services, is pleased to announce receipt of a 2014 Lilly Global Supplier Award.
Dr. Stephen Munk, Ash Stevens' President & CEO said, "We are honored to receive this award and recognition from Eli Lilly and Company. Ash Stevens has a rich history that exceeds 50 years conducting innovative chemical research to develop and manufacture a wide variety of active pharmaceutical ingredients. We are proud to have Lilly as a valued customer."
About Ash Stevens, Inc.
Ash Stevens, Inc. is a full service pharmaceutical Contract Manufacturing Organization (CMO) offering comprehensive small-molecule drug substance development and cGMP manufacturing services. Founded in 1962 and headquartered in Riverview, Michigan, Ash Stevens has extensive experience developing and manufacturing Active Pharmaceutical Ingredients (APIs) for Life Science companies that develop innovator small-molecule therapeutics. Ash Stevens is a long-time provider of contract research services to the National Institutes of Health and the National Cancer Institute, and has participated in the development of many important drugs through these Government agencies. To date, Ash Stevens has received twelve FDA manufacturing approvals for innovator APIs, including four fast-track manufacturing approvals for the active ingredients in the oncology drugs Velcade®, Vidaza®, Clolar® and Iclusig®. Services offered by Ash Stevens include process development and scale-up; cGMP manufacturing; development and cGMP manufacture of highly potent APIs using barrier-isolation technology; comprehensive analytical capabilities (including method development, stability studies and qualification of reference standards); and regulatory support for all phases of drug development and manufacturing.
©2012 PR Newswire. All Rights Reserved.